Related Experiment Videos
Exploring the Treatment Outcomes and Safety of Elobixibat for Chronic Constipation: A Systematic Review and
Maggie Liberty1, Taufik Sungkar2, Peggy Liberty3
1Faculty of Medicine, Universitas Sumatera Utara. maggieliberty288@gmail.com.
Background:
Currently available laxatives usage in chronic constipation (CC) has been reported to cause various adverse events, notably melanosis coli and colonic neuromuscular disorder. Elobixibat, an ileal bile acid transporter inhibitor, appears to be a promising option for chronic constipation to counteract this challenge. This study aims to evaluate the treatment outcome and safety of elobixibat for chronic constipation.
Methods:
This systematic review and meta-analysis were performed on 3 search engines: PubMed/MEDLINE, ScienceDirect, and Cochrane Database of Systematic Reviews. Randomized controlled trials (RCTs) comparing elobixibat 10 mg with placebo in patients with functional chronic constipation were included. The quality of studies was assessed using the Cochrane risk of bias 2.0 tool. Statistical analyses were conducted using RevMan 5.4.1 software.
Results:
A total of six RCTs that met the inclusion criteria were included in this study. Results demonstrated that elobixibat markedly improved bowel movement with a significant change in spontaneous bowel movement (SBM) (MD 2.91, 95% CI 2.81 to 3.01, p<0.00001) and complete spontaneous bowel movement (MD 0.61, 95% CI 0.38 to 0.83, p<0.00001). The percentage of patients experiencing first SBM in 24 hours was significantly higher in the elobixibat group compared to the placebo group (RR 1.49, 95% CI 1.21 to 1.84, p=0.0002). Stool consistency was improved significantly in the elobixibat group (MD 1.40, 95% CI 1.09 to 1.71, p<0.00001). Moreover, the elobixibat group reported favourable safety with no serious adverse events.
Conclusion:
Elobixibat shows promising therapeutic efficacy in the treatment of functional chronic constipation. Elobixibat is safe and well-tolerated with minimal adverse events.
Related Concept Videos
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs Affecting GI Tract Motility: Other Laxatives
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...